Maximum slope using ultrafast breast DCE-MRI at 1.5 Tesla: a potential tool for predicting breast lesion aggressiveness.

OBJECTIVES: We evaluated the relationship between the maximum slope (MS) based on ultrafast breast DCE-MRI sequences, and the clinical parameters and routine prognostic factors of breast cancer. METHODS: 210 lesions were retrospectively evaluated: 150 malignant (30 each of luminal A invasive carcinoma, luminal B invasive carcinoma, HER2 overexpression (HER2), triple negative (TN), invasive lobular carcinoma (ILC)), and 60 benign. For each lesion, the MS was obtained with an ultrafast sequence and semi-quantitative curves were classified into three types with a conventional DCE sequence. The correlation between MS and age, body mass index (BMI), menopause, and routine prognostic factors were analyzed. RESULTS: A MS cut-off at 6.5%/s could discriminate benign from malignant lesions, with sensitivity and specificity of 84% and 90%, respectively, whereas analysis of semi-quantitative curves showed sensitivity and specificity of 89.3% and 55%, respectively. In multivariate analysis, MS values decreased with BMI increasing (p = 0.035), postmenopausal status (p < 0.001), and positive ER status (p < 0.001) and increased with tumor size (p < 0.001). The MS was significantly lower for the pooled luminal A + ILC group than for the pooled luminal B + HER2 + TN group featuring tumors with poorer prognoses (p < 0.001). With a threshold of 11%/s, the sensitivity and specificity to identify invasive carcinoma subtypes with poorer prognoses were 71% and 68%, respectively. CONCLUSION: The MS allows better tumor characterization and identifies factors of poor prognosis for breast cancer. KEY POINTS: • Maximum slope calculated from ultrafast breast DCE-MRI differentiates benign from malignant breast lesions better than semi-quantitative curves of conventional DCE-MRI. • Maximum slope calculated from ultrafast breast DCE-MRI identifies breast cancers with poor prognoses. • In the case of multiple lesions, the most aggressive may be identified and targeted by measuring the maximum slope.

Evaluation of pre-therapeutic imaging work-up in the staging of endometrial cancer: Interest in a systematic second opinion in a cancer center.

RATIONALE AND OBJECTIVES: To evaluate the interest of a systematic second opinion in quality assessment and FIGO staging in the pretherapeutic imaging work-up. MATERIALS AND METHODS: A retrospective observational study was conducted on 156 patients who underwent surgery for endometrioid cancer in our institution. 42 % had their initial MRI scans performed in expert centers (University Hospital and Cancer center) and 58 % in non-expert centers. Quality assessment, concordances between initial reports, and second opinions by a junior and a senior ICL radiologist versus histopathological data were analyzed. RESULTS: MRI scans performed in expert centers were more complete and more likely to be rated as higher quality. The overall accuracy of T staging from initial reports vs gold standard was 0.59 (95 % CI, 0.46-0.71) in expert centers and 0.49 (95 % CI, 0.38-0.60) in non-expert centers. The overall accuracy and Kappa of a second opinion for FIGO 2009 staging from expert center and non-expert center examinations were 0.61 (95 % CI, 0.48-0.72) vs 0.50 (95 % CI, 0.39-0.60) and 0.37 vs 0.27 for junior reader and 0.62 (95 % CI, 0.49-0.74) vs 0.48 (95 % CI, 0.37-0.58) and 0.39 vs 0.24 for senior reader, respectively. There was also a significant lower confidence level of the junior radiologist in MRI FIGO staging for non-expert center examinations (p 0.003). CONCLUSION: Accuracy in the FIGO 2009 staging and quality assessment are higher for MR examinations performed from expert centers than in non-expert centers. A systematic second opinion by radiologists in expert centers should be proposed before pre-treatment multidisciplinary consultation.